Indiana Biosciences Research Institute

The Indiana Biosciences Research Institute (IBRI) is an American nonprofit translational research organization headquartered in Indianapolis, Indiana, United States within the 16 Tech Innovation District. The IBRI is the nation's first industry-led collaborative life sciences research institute. Its primary focus is on better understanding the pathogenesis of type 1 and type 2 diabetes to translate this knowledge into novel therapies, while also expanding into other metabolic diseases that share common systems and pathways.

History
In 2012, pharmaceutical executive John C. Lechleiter from Eli Lilly & Company initially proposed the IBRI. In 2013, Indiana governor Mike Pence announced the formation of the IBRI. Pence later worked with life sciences leaders to secure $25 million in startup funds from the state.

In 2015, the IBRI hired David Broecker as CEO. In late 2015, the Indianapolis City-County Council approved $75 million to build a technology park called 16 Tech. In 2016, the IBRI hired Rainer Fischer as Chief Scientific Officer. In 2017, Governor Eric Holcomb reaffirmed the commitment made by his predecessor Mike Pence.

Leadership
Appointees to the IBRI’s Board of Directors include:
 * Robert Bernhard, University of Notre Dame
 * Wayne Burris, Roche Diagnostics
 * Kenneth Custer, Eli Lilly & Company
 * Daniel Evans Jr., Indiana University Health
 * Tatiana Foroud, Indiana University School of Medicine
 * Jay Hess, Indiana University
 * David Ingram, Indiana University Health
 * Cris Johnston, Indiana Office of Management and Budget
 * John Lechleiter, Eli Lilly & Company
 * Patricia Martin, BioCrossroads, Inc.
 * Theresa Mayer, Purdue University
 * Hany Moselhi, Roche Diagnostics
 * Alan Palkowitz, IBRI
 * Dan Peterson, Cook Group
 * Aaron Schacht, BiomEdit, LLC
 * Wendy Srnic, Corteva
 * Bill Stephan, Indiana University